NEW YORK / Mar 01, 2024 / Business Wire / As required by the rules of the New York Stock Exchange, MultiPlan Corporation (NYSE:MPLN) (“MultiPlan” or the “Company”) today announced that it has granted to Travis Dalton, the Company’s recently appointed President and Chief Executive Officer, on March 1, 2024, employment inducement awards consisting of the following: (i) 6,849,315 with such options vesting over a three-year period from March 1, 2024, in substantially equal annual installments, subject to Mr. Dalton’s continued employment; and (ii) 4,504,504 restricted stock units with such units vesting over a two-year period from March 1, 2024, in substantially equal annual installments, subject to Mr. Dalton’s continued employment. These awards were granted to Mr. Dalton pursuant to the terms of his employment agreement, which was disclosed by the Company on a Form 8-K filed with the SEC on January 4, 2024.
These awards were granted outside the Plan, but except as set forth in the award agreements, will generally be subject to the same terms and conditions as apply to the applicable awards granted under the Company’s 2020 Omnibus Incentive Plan. The Compensation Committee of MultiPlan’s Board of Directors approved these employment inducement awards in reliance on the employment inducement exception to shareholder approval provided under Section 303A.08 of the NYSE Listed Company Manual. To comply with the terms of this exemption, these employment inducement awards require public announcement of the awards and written notice to the NYSE.
About MultiPlan
MultiPlan is committed to delivering affordability, efficiency, and fairness to the US healthcare system by helping healthcare payors manage the cost of care, improve their competitiveness and inspire positive change. Leveraging sophisticated technology, data analytics and a team rich with industry experience, MultiPlan interprets customers’ needs and customizes innovative solutions that combine its payment and revenue integrity, network-based and analytics-based, and data and decision science services. MultiPlan is a trusted partner to over 700 healthcare payors, brokers, employer groups, and supplemental carriers in the commercial health, government, and property and casualty markets. For more information, visit multiplan.com.
Last Trade: | US$29.20 |
Daily Volume: | 0 |
Market Cap: | US$472.160M |
February 25, 2025 January 10, 2025 December 24, 2024 November 05, 2024 October 03, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load